HPLC in FDA Warning Letters

Recommendation
7/8 October 2025
Performance Evaluation and Monitoring for compliant Analytical Procedures and Processes
In the current compilation of Warning Letters issued between 2009 and 2011 we have summarised for you the key points regarding the use of high performance liquid chromatography (HPLC).
The inspection focuses can be summarised and compiled in the following 4 themes:
- Raw Data / Protection of Electronic Records
- Calibration / Qualification
- Method Validation
- System Suitability / Sequences
Author:
Dr Günter Brendelberger
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
17.09.2025USP-NF Stimuli Article on Apex Vessels used in Dissolution Testing: Corrected Version Published
17.09.2025Who is allowed to perform Sampling?
27.08.2025FDA Warning Letter: Missing Identity Tests, Unverified CoAs, and Inadequate DEG/EG Controls
20.08.2025USP Responds to Comments on Chapter <202> HPTLC Identification of Fixed Oils
13.08.2025USP publishes Comments rereived on Chapter <317>
13.08.2025FDA Issues Warning Letter to Contract Testing Laboratory for Inadequate OOS Investigations